Health Economics›Esophageal adenocarcinoma›Metastatic or locally advanced disease first-line

Metastatic or locally advanced disease first-line

Esophageal adenocarcinoma · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 11 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Capecitabine and Cisplatin (CX) and Cetuximab Variant #01	—	R 53 477	21d	4.4 mo	—	7	R 374 342 PFS proxy	1
Erlotinib monotherapy Variant #01	—	R 13 907	28d	~9.7 mo	~8.8 mo	~11	~R 152 976 PFS proxy · indirect	30
FLOT Variant #03	—	R 7 216	21d	—	~50.0 mo	—	—	2
Irinotecan and Mitomycin Variant #01	—	R 2 896	28d	—	—	—	—	—
FOLFIRI Variant #05	—	R 2 826	14d	~8.2 mo	~16.1 mo	~18	~R 50 875 PFS proxy · indirect	22
mFOLFOX6 and Nivolumab Variant #01 Partial	—	R 2 586	14d	7.7 mo	14.4 mo	17	R 43 964 PFS proxy	2
mFOLFOX6 Variant #02	—	R 2 466	14d	—	11.6 mo	—	—	—
CapeOx and Nivolumab Variant #01 Partial	—	R 2 384	21d	7.7 mo	14.4 mo	12	R 28 611 PFS proxy	2
CapeOx Variant #01	—	R 2 384	21d	~6.7 mo	~12.2 mo	~10	~R 23 842 PFS proxy · indirect	20
ECX Variant #01	—	R 2 313	21d	4.2 mo	—	7	R 16 189 PFS proxy	1
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	—	8.6 mo	—	—	1
FOLFOX6 Variant #01	—	R 1 750	14d	~6.7 mo	—	~15	~R 26 250 PFS proxy · indirect	—
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 1 629	14d	—	11.8 mo	—	—	—
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 386	21d	5.6 mo	—	9	R 12 478 PFS proxy	1
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	~2.3 mo	~8.5 mo	~2	~R 95 PFS proxy · indirect	16
CAPIRI N/A - secondary systemic drug	—	R 1	21d	~5.9 mo	~16.8 mo	~9	~R 12 PFS proxy · indirect	2

16 of 16 regimens shown